INmune Bio Phase 2 Trial In Alzheimers Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha

INMB Stock  USD 9.22  0.16  1.77%   
About 56% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  
INmune Bio Phase 2 Trial In Alzheimers Disease Is My Highest Risk-Reward Bet Of 2025 Seeking Alpha

Read at news.google.com
Google News at Macroaxis
  

INmune Bio Fundamental Analysis

We analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

INmune Bio is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

INmune Bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with INmune Bio stock to make a market-neutral strategy. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics with similar companies.

Peers

INmune Bio Related Equities

CUECue Biopharma   6.62   
0%
100.0%
INABIn8bio   4.00   
0%
60.0%
SAVACassava Sciences   3.03   
0%
45.0%
DRMADermata Therapeutics   2.50   
0%
37.0%
AVTEAerovate Therapeutics   1.55   
0%
23.0%
TCRXTscan Therapeutics   0.39   
5.0%
0%
ANIXAnixa Biosciences   2.00   
30.0%
0%
ANTXAN2 Therapeutics   2.56   
38.0%
0%
AVXLAnavex Life   3.13   
47.0%
0%
ANEBAnebulo Pharmaceuticals   3.14   
47.0%
0%
BIVIBiovie   3.47   
52.0%
0%
PYPDPolyPid   4.35   
65.0%
0%
CGTXCognition Therapeutics   6.49   
98.0%
0%

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine